Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Equity Capital Markets

Shaanxi Micot Pharmaceutical Technology / Equity Capital Markets

Shaanxi Micot Pharmaceutical Technology (SMP HK)

<ul>
<li>Shaanxi Micot Pharmaceutical Technology, a clinical-stage biotechnology company, has launched HK IPO consisting of 58M H shares. The indicative offer price range has been fixed at HK$18.20–21.00 per share.</li>
<li>The company intends to raise HK$1,219M, primarily to fund ongoing and planned clinical trials and planned commercial launch of core and key product candidates.</li>
<li>The subscription period will close on June 18, with the shares expected to make trading debut on June 24. CCB International and CMS are the joint sponsors to the issue.</li>
</ul>


Shaanxi Micot Pharmaceutical Technology, a clinical-stage biotechnology company, has launched HK IPO consisting of 58M H shares. The indicative offer price range has been fixed at HK$18.20–21.00 per share.
The company intends to raise HK$1,219M, primarily to fund ongoing and planned clinical trials and planned commercial launch of core and key product candidates.
The subscription period will close on June 18, with the shares expected to make trading debut on June 24. CCB International and CMS are the joint sponsors to the issue.


Micot Pharmaceutical IPO: Sizable End Market and Product Superiority to Drive Sustainable Growth